Bio-Rad signs deal with DiaMed:
This article was originally published in Clinica
Executive Summary
Life science research and clinical diagnostics specialist Bio-Rad last week signed a definitive agreement to acquire 77.7% of shares in DiaMed, a Swiss test system manufacturer. The agreement will see Bio-Rad pay SFr477m ($389m) in cash for the shares; DiaMed will retain 9.6% of its stock as treasury shares, while Bio-Rad will offer to purchase the remaining 12.7% after the initial deal has been closed later this year. Bio-Rad (Hercules, California) will inherit from DiaMed a comprehensive line of reagents and instruments, used in blood typing and screening, which generated annual revenues of approximately $200m from sales to hospitals, clinical labs and blood banks in over 100 countries.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.